{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:46:40Z","timestamp":1792072000461,"version":"4.4.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title\/>\n                  <jats:p>\n                    Women who inherit a germline mutation in a hereditary breast and ovarian cancer syndrome gene are recommended to have their fallopian tubes and ovaries removed 5\u201315 years before the age of natural menopause to prevent the development of ovarian or fallopian tube cancer. Early surgical menopause can lead to several acute and chronic health implications, and, although menopausal hormone therapy (MHT) remains the most effective way to mitigate these issues, use remains suboptimal. This is particularly discernible in populations who face extremely high lifetime risks of developing breast cancer, likely related to the misinformation surrounding its use on subsequent breast cancer risk. Here, we provide a summary of the literature on MHT use and breast cancer as it pertains to high-risk populations, notably\n                    <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>\n                    mutation carriers. We also introduce our intention to evaluate how newer formulations such as conjugated estrogen combined with the selective estrogen receptor modulator bazedoxifene may treat symptoms, maintain bone health, and potentially decrease breast cancer risk. Results would be transformative for menopause management in women with hereditary breast and ovarian cancer syndrome and inform guidelines on the safety of MHT in this unique population.\n                  <\/jats:p>","DOI":"10.1097\/aog.0000000000006429","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:00:23Z","timestamp":1789502423000},"page":"3296-e306","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Menopausal Hormone Therapy After Risk-Reducing Salpingo-Oophorectomy in Women at High Risk for Breast Cancer"],"prefix":"10.1097","volume":"148","author":[{"given":"Stephanie M.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Kotsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"R1-20261015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N Engl J Med"},{"key":"R2-20261015","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J Clin Oncol"},{"key":"R3-20261015","doi-asserted-by":"crossref","first-page":"e182140","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult biobank participants","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"key":"R4-20261015","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1200\/JCO.2016.67.0554","article-title":"Population frequency of germline BRCA1\/2 mutations","volume":"34","author":"Maxwell","year":"2016","journal-title":"J Clin Oncol"},{"key":"R5-20261015","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41436-018-0277-0","article-title":"Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility","volume":"21","author":"Rowley","year":"2019","journal-title":"Genet Med"},{"key":"R6-20261015","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"R7-20261015","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N Engl J Med"},{"key":"R8-20261015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"Tung","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R9-20261015","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"R10-20261015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10689-016-9919-z","article-title":"Frequency of germline PALB2 mutations among women with epithelial ovarian cancer","volume":"16","author":"Kotsopoulos","year":"2017","journal-title":"Fam Cancer"},{"key":"R11-20261015","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet"},{"key":"R12-20261015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN Guidelines\u00ae insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R13-20261015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"key":"R14-20261015","doi-asserted-by":"crossref","first-page":"101557","DOI":"10.1016\/j.gim.2025.101557","article-title":"Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"27","author":"Ngeow","year":"2025","journal-title":"Genet Med"},{"key":"R15-20261015","doi-asserted-by":"crossref","first-page":"e2355324","DOI":"10.1001\/jamanetworkopen.2023.55324","article-title":"Cost-Effectiveness of gene-specific prevention strategies for ovarian and breast cancer","volume":"7","author":"Wei","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R16-20261015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"R17-20261015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/jamaoncol.2023.6937","article-title":"Bilateral oophorectomy and all-cause mortality in women with BRCA1 and BRCA2 sequence variations","volume":"10","author":"Kotsopoulos","year":"2024","journal-title":"JAMA Oncol"},{"key":"R18-20261015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","article-title":"International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation","volume":"121","author":"Metcalfe","year":"2019","journal-title":"Br J Cancer"},{"key":"R19-20261015","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaoncol.2021.1590","article-title":"Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1\/2 pathogenic variant carriers: a nonrandomized controlled trial","volume":"7","author":"Steenbeek","year":"2021","journal-title":"JAMA Oncol"},{"key":"R20-20261015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2018.10.040","article-title":"Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation","volume":"152","author":"Hall","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R21-20261015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/GME.0000000000001437","article-title":"Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?","volume":"27","author":"Kotsopoulos","year":"2020","journal-title":"Menopause"},{"key":"R22-20261015","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S1470-2045(06)70869-5","article-title":"Survival patterns after oophorectomy in premenopausal women: a population-based cohort study","volume":"7","author":"Rocca","year":"2006","journal-title":"Lancet Oncol"},{"key":"R23-20261015","doi-asserted-by":"crossref","first-page":"e198420","DOI":"10.1001\/jamanetworkopen.2019.8420","article-title":"Changes in bone mineral density after prophylactic bilateral salpingo-oophorectomy in carriers of a BRCA mutation","volume":"2","author":"Kotsopoulos","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R24-20261015","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/GME.0000000000001629","article-title":"Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers","volume":"27","author":"Mejia-Gomez","year":"2020","journal-title":"Menopause"},{"key":"R25-20261015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/13697137.2023.2173567","article-title":"BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations","volume":"26","author":"Armon","year":"2023","journal-title":"Climacteric"},{"key":"R26-20261015","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/jnci\/djaf363","article-title":"Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2","volume":"118","author":"Kotsopoulos","year":"2026","journal-title":"J Natl Cancer Inst"},{"key":"R27-20261015","doi-asserted-by":"crossref","first-page":"e243135","DOI":"10.1001\/jamahealthforum.2024.3135","article-title":"Recent trends in menopausal hormone therapy use in the US: insights, disparities, and implications for practice","volume":"5","author":"Iyer","year":"2024","journal-title":"JAMA Health Forum"},{"key":"R28-20261015","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/GME.0000000000001945","article-title":"Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis","volume":"29","author":"Pan","year":"2022","journal-title":"Menopause"},{"key":"R29-20261015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/AOG.0000000000005907","article-title":"Menopausal symptom management in patients after risk-reducing oophorectomy","volume":"146","author":"Kaunitz","year":"2025","journal-title":"Obstet Gynecol"},{"key":"R30-20261015","doi-asserted-by":"crossref","first-page":"108911","DOI":"10.1016\/j.maturitas.2026.108911","article-title":"Impact of concomitant hysterectomy on quality of life in BRCA carriers undergoing risk-reducing salpingo-oophorectomy","volume":"208","author":"Nahshon","year":"2026","journal-title":"Maturitas"},{"key":"R31-20261015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ygyno.2024.07.687","article-title":"Incidence of endometrial cancer in BRCA mutation carriers","volume":"189","author":"Kotsopoulos","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R32-20261015","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/jnci\/djab036","article-title":"Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations: multicenter cohort study","volume":"113","author":"de Jonge","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"R33-20261015","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jogc.2018.05.046","article-title":"No. 366\u2013gynaecologic management of hereditary breast and ovarian cancer","volume":"40","author":"Jacobson","year":"2018","journal-title":"J Obstet Gynaecol Can"},{"key":"R34-20261015","first-page":"e16","article-title":"Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66","volume":"129","author":"Manchanda","year":"2022","journal-title":"BJOG"},{"key":"R35-20261015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/GME.0000000000002154","article-title":"The Women's Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context","volume":"30","author":"Chlebowski","year":"2023","journal-title":"Menopause"},{"key":"R36-20261015","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJMoa0807684","article-title":"Breast cancer after use of estrogen plus progestin in postmenopausal women","volume":"360","author":"Chlebowski","year":"2009","journal-title":"N Engl J Med"},{"key":"R37-20261015","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"},{"key":"R38-20261015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1124\/mol.115.100925","article-title":"The dual estrogen receptor alpha inhibitory effects of the tissue-selective estrogen complex for endometrial and breast safety","volume":"89","author":"Han","year":"2016","journal-title":"Mol Pharmacol"},{"key":"R39-20261015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.1.5844.13","article-title":"Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels","volume":"1","author":"Ward","year":"1973","journal-title":"Br Med J"},{"key":"R40-20261015","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R41-20261015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1677\/joe.0.0680297","article-title":"Tamoxifen as an anti-tumour agent: effect on oestrogen binding","volume":"68","author":"Jordan","year":"1976","journal-title":"J Endocrinol"},{"key":"R42-20261015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-6632.2001.tb04007.x","article-title":"The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1)","volume":"949","author":"Wolmark","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"R43-20261015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1749-6632.2001.tb04027.x","article-title":"The effect of SERMs on the endometrium","volume":"949","author":"Goldstein","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"R44-20261015","first-page":"346","article-title":"Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy","volume":"101","author":"Parsons","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R45-20261015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"R46-20261015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3109\/13697137.2012.717994","article-title":"Effects of bazedoxifene\/conjugated estrogens on endometrial safety and bone in postmenopausal women","volume":"16","author":"Mirkin","year":"2013","journal-title":"Climacteric"},{"key":"R47-20261015","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/gme.0b013e3181a7df0d","article-title":"Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene\/conjugated estrogens: a randomized, controlled trial","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"key":"R48-20261015","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.maturitas.2016.09.010","article-title":"Direct and indirect effects of conjugated estrogens\/bazedoxifene treatment on quality of life in postmenopausal women","volume":"94","author":"Abraham","year":"2016","journal-title":"Maturitas"},{"key":"R49-20261015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1940-6207.CAPR-19-0315","article-title":"Effect of bazedoxifene and conjugated estrogen (Duavee) on breast cancer risk biomarkers in high-risk women: a pilot study","volume":"12","author":"Fabian","year":"2019","journal-title":"Cancer Prev Res (Phila)"},{"key":"R50-20261015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.2025.43.16_suppl.512","article-title":"The promise study: a presurgical randomized clinical trial of CE\/BZA vs placebo in postmenopausal women with ductal carcinoma in situ","volume":"43","author":"Kulkarni","year":"2025","journal-title":"J Clin Oncol"},{"key":"R51-20261015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jnci\/djh106","article-title":"Tamoxifen and breast density in women at increased risk of breast cancer","volume":"96","author":"Cuzick","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R52-20261015","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1200\/JCO.20.02598","article-title":"Low-dose tamoxifen for mammographic density reduction: a randomized controlled trial","volume":"39","author":"Eriksson","year":"2021","journal-title":"J Clin Oncol"},{"key":"R53-20261015","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/1471-0528.17511","article-title":"Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: scoping review and international consensus recommendations","volume":"130","author":"Nebgen","year":"2023","journal-title":"BJOG"},{"key":"R54-20261015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"R55-20261015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.6004\/jnccn.2026.0007","article-title":"NCCN Guidelines\u00ae insights: genetic\/familial high-risk assessment: breast, ovarian, pancreatic, and prostate, version 2.2026","volume":"24","author":"Cheng","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"R56-20261015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R57-20261015","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","article-title":"Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D","volume":"112","author":"Yang","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"R58-20261015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes\u2013association analysis in more than 113,000 women","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med"},{"key":"R59-20261015","doi-asserted-by":"crossref","first-page":"e247811","DOI":"10.1001\/jamanetworkopen.2024.7811","article-title":"Prevalence of homologous recombination deficiency among patients with germline RAD51C\/D breast or ovarian cancer","volume":"7","author":"Torres-Esquius","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R60-20261015","doi-asserted-by":"crossref","first-page":"e0186043","DOI":"10.1371\/journal.pone.0186043","article-title":"Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1)","volume":"12","author":"Harter","year":"2017","journal-title":"PLoS One"},{"key":"R61-20261015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2023.07.017","article-title":"Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: a systematic review and meta-analysis","volume":"177","author":"Narayan","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R62-20261015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-020-00654-3","article-title":"BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of \u223c30,000 cases","volume":"13","author":"Suszynska","year":"2020","journal-title":"J Ovarian Res"},{"key":"R63-20261015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R64-20261015","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"key":"R65-20261015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"R66-20261015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/gme.0b013e3181b7c65f","article-title":"A randomized, placebo- and active-controlled trial of bazedoxifene\/conjugated estrogens for treatment of moderate to severe vulvar\/vaginal atrophy in postmenopausal women","volume":"17","author":"Kagan","year":"2010","journal-title":"Menopause"},{"key":"R67-20261015","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R68-20261015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"R69-20261015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"R70-20261015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-016-4029-z","article-title":"Can we prevent BRCA1-associated breast cancer by RANKL inhibition?","volume":"161","author":"Kotsopoulos","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"R71-20261015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/0008-5472.CAN-16-2025","article-title":"Out-RANKing BRCA1 in mutation carriers","volume":"77","author":"Nolan","year":"2017","journal-title":"Cancer Res"},{"key":"R72-20261015","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S1470-2045(13)70448-0","article-title":"The sex hormone system in carriers of BRCA1\/2 mutations: a case-control study","volume":"14","author":"Widschwendter","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:02:26Z","timestamp":1792069346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006429","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"2026-04-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}